BOT 16.9% 38.0¢ botanix pharmaceuticals ltd

Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-548

  1. 231 Posts.
    lightbulb Created with Sketch. 38
    The FDA will not be concerned by efficacy they will only be concerned by safety and the drug we know has a very good safety profile. The efficacy will be now determined by the Phase 3 trial. The difficulty is we need a CR to fund a phase 3 trial with enough power. I know they have cash at hand but I think they will be using this for the other irons they have in the fire but a good question to ask at the AGM
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
38.0¢
Change
0.055(16.9%)
Mkt cap ! $687.8M
Open High Low Value Volume
33.0¢ 38.0¢ 33.0¢ $7.103M 19.63M

Buyers (Bids)

No. Vol. Price($)
5 134000 37.5¢
 

Sellers (Offers)

Price($) Vol. No.
38.0¢ 650314 19
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.